0001193125-23-130403 | 20-F | XBRL Viewer

Valuation technique

Significant

unobservable inputs

Inter-relationship

between significant
unobservable inputs and

fair value measurement

Financial assets at fair value through profit or loss

Adjusted net asset value

Underlying assets’ value

The estimated fair value would increase if the underlying assets’ value is higher

Preference shares liabilities - conversion feature

Discounted cash flow and equity allocation method: the conversion feature is measured by deducting the present value of the expected redemption amount from the fair value of the preferred shares.

The fair value of the preference shares is determined by applying the equity allocation method to the total equity value of the Group estimated based on the net present value of future cash flows.

Risk-adjusted discount rate adopted in the discounted cashflow method for the valuation of equity interest: 15.90%

Discount for lack of marketability: 12%

Expected volatility adopted in the equity allocation method: 41.03%

The estimated fair value would increase (decrease) if:

• the risk-adjusted discount rate was lower (higher);

• the discount for lack of marketability was lower (higher); or

• the expected volatility was higher (lower)

Use of estimates

12 Months Ended

Dec. 31, 2022

4	Use of estimates

In preparing these consolidated financial statements, management has made estimates that affect the application of the Group’s accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to estimates are recognized prospectively.

Assumptions and estimation uncertainties

Information about assumptions and estimation uncertainties at the reporting date that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next financial year is included in the following notes:

Notes 12 and 13: impairment test of cash generating units containing goodwill and intangible assets: key assumptions underlying recoverable amounts, including the recoverability of development costs; and

Note 33: acquisition of ACT Genomics Holdings Company Limited and its subsidiaries (“ACT Group”): fair value of the assets acquired and liabilities assumed.

Measurement of fair values

A number of the Group’s accounting policies and disclosures require the measurement of fair values, for both financial and

non-financial

assets and liabilities.

The Group assigned its finance team to oversee all significant fair value measurements, including Level 3 fair values, and reports directly to the chief financial officer.

The finance team regularly reviews significant unobservable inputs and valuation adjustments. If third party information, such as broker quotes or pricing services, is used to measure fair values, then the finance team assesses the evidence obtained from the third parties to support the conclusion that these valuations meet the requirements of the IFRSs, including the level in the fair value hierarchy in which the valuations should be classified.

Significant valuation issues are reported to the Group’s audit committee.

When measuring the fair value of an asset or a liability, the Group uses observable market data as far as possible. Fair values are categorised into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows.

•

Level

quoted prices (unadjusted) in active markets for identical assets or liabilities.

•

Level

inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

•

Level

: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the fair value measurement is categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement.

The Group recognises transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred.

Further information about the assumptions made in measuring fair values is included in the following notes:

•

Note 29: equity-settled share-based transactions;

•

Note 31(B): financial instruments; and

•

Notes 13 and 33: acquisition of ACT Group.

Liabilities for puttable financial instrument - Schedule of liabilities for puttable financial instrument (Details)	Dec. 31, 2022 USD ($)
Liabilities for puttable financial instrument [Abstract]
Beginning balance	$ 0
Ending balance	$ 17,138,905

Cover Page	12 Months Ended
Cover Page	Dec. 31, 2022 shares
Document Information [Line Items]
Document Type	20-F
Amendment Flag	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--12-31
Entity Registrant Name	Prenetics Global Limited
Entity Filer Category	Accelerated Filer
Entity File Number	001-41401
Entity Well-known Seasoned Issuer	No
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Document Registration Statement	false
Document Accounting Standard	International Financial Reporting Standards
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Address, Address Line One	Unit 701-706, K11 Atelier King’s Road
Entity Address, Address Line Two	728 King’s Road
Entity Central Index Key	0001876431
Entity Address, Country	HK
Entity Address, City or Town	Quarry Bay
Entity Incorporation, State or Country Code	E9
Security Exchange Name	NASDAQ
Title of 12(b) Security	Warrants
Entity Common Stock, Shares Outstanding	136,983,110
Trading Symbol	PRENW
Entity Address, Postal Zip Code	000000
ICFR Auditor Attestation Flag	false
Entity Ex Transition Period	false
Auditor Name	KPMG
Auditor Firm ID	1181
Auditor Location	Hong Kong
Business Contact [Member]
Document Information [Line Items]
Entity Address, Address Line One	Unit 701-706, K11 Atelier King’s Road
Entity Address, Address Line Two	728 King’s Road
Entity Address, Country	HK
Entity Address, City or Town	Quarry Bay
City Area Code	852
Local Phone Number	2210-9588
Entity Address, Postal Zip Code	000000
Contact Personnel Name	Stephen Lo, Chief Financial Officer
Contact Personnel Email Address	stephen.lo@prenetics.com

Short-term deposits and cash and cash equivalents

12 Months Ended

Dec. 31, 2022

Disclosure Of Short Term Deposits And Cash And Cash Equivalents [Abstract]

Short-term deposits and cash and cash equivalents

19	Short-term deposits and cash and cash equivalents

See accounting policies in notes 36(J)(i)-(ii) and (L)(i).

(a)	Short-term deposits

At December 31, 2022, the short-term deposits of the Group carried weighted average interest rates of 5.21% per annum (2021: nil).

(b)	Cash and cash equivalents


	2022 $		2021 $
Bank balances		146,656,326		35,288,761
Cash on hand		3,869		191

Cash and cash equivalents		146,660,195		35,288,952

Related parties - Transactions with key management personnel (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Related party transactions
Legal and professional fee paid on behalf of related companies	$ 0	$ 9,060	$ 0

Warrant liabilities (Tables)

12 Months Ended

Dec. 31, 2022

Warrant Liabilities [Abstract]

Summary of Movement in Warrant Liabilities

Movement of the balance during the year ended December 31, 2022 is as follow:


	2022
	$
At January 1		—
Assumption of warrant upon the Reverse Recapitalization		6,186,423
Issuance of warrant		585,000
Change in fair value recognized in profit or loss		(3,196,538	)

At December 31		3,574,885

Reverse Recapitalization - Summary of fair value of Artisan's identifiable net assets acquired (Parenthetical) (Details) - $ / shares	Dec. 31, 2022	Mar. 30, 2022	Sep. 15, 2021
Disclosure Of Fair Value Of Artisans Identifiable Net Assets Acquired With The Amount Expensed As Incurred [Line Items]
Class of warrants issued during the period	1,500,000
Number Of Warrant Issued Upon Conversion	1,500,000
Reverse Recapitalization [Member]
Disclosure Of Fair Value Of Artisans Identifiable Net Assets Acquired With The Amount Expensed As Incurred [Line Items]
Sale of stock price per share	$ 585,000
Private Placement Warrant [Member]
Disclosure Of Fair Value Of Artisans Identifiable Net Assets Acquired With The Amount Expensed As Incurred [Line Items]
Class of warrants issued during the period	375,000
Class A ordinary shares [Member]
Disclosure Of Fair Value Of Artisans Identifiable Net Assets Acquired With The Amount Expensed As Incurred [Line Items]
Sale of stock price per share	$ 10	$ 55,800,000	$ 10
Shares Issued upon Conversion	6,000,000		7,740,000
Redeemable Warrants [Member]
Disclosure Of Fair Value Of Artisans Identifiable Net Assets Acquired With The Amount Expensed As Incurred [Line Items]
Class of warrants issued during the period	1,500,000

Reverse Recapitalization - Summary of fair value of Artisan's identifiable net assets acquired (Details)	Dec. 31, 2022 USD ($)
Disclosure Of Fair Value Of Artisans Identifiable Net Assets Acquired With The Amount Expensed As Incurred [Line Items]
Warrants liabilities (note (i))	$ (6,186,423)

Financial instruments-Fair values and risk management (Tables)

12 Months Ended

Dec. 31, 2022

Financial risk management and fair values of financial instruments

Schedule of carrying amounts and fair values of financial assets and financial liabilities

The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy. It does not include fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value.


	Note		2022		2021
			$		$
Financial asset measured at fair value
Financial assets at FVPL		1 8		17,537,608		9,906,000

Financial assets at amortized cost
Trade receivables		1 7		41,691,913		47,041,538
Deposits and other receivables		15, 1 7		8,181,576		8,511,304
Amounts due from related companies				—		9,060
Cash and cash equivalents		19(b)		146,660,195		35,288,952

				196,533,684		90,850,854

Financial liabilities measured at fair value
Preference shares liabilities		2 5		—		486,404,770
Warrant liabilities		2 6		3,574,885		—

				3,574,885		486,404,770

Financial liabilities at amortized cost
Trade payables				7,291,133		9,979,726
Accrued expenses and other liabilities		20		15,668,734		36,280,298

Liabilities for puttable financial instrument		27		17,138,905		—
				40,098,772		46,260,024

Schedule of remaining contractual maturities at the end of the reporting period of the non-derivative financial liabilities and derivative financial liabilities, which are based on contractual undiscounted cash flows

The following table shows the remaining contractual maturities at the end of the reporting period of the Group’s

non-derivative

financial liabilities and derivative financial liabilities, which are based on contractual undiscounted cash flows (including interest payments computed using contractual rates or, if floating, based on rates current at the end of the reporting period) and the earliest date the Group can be required to pay:


			Contractual undiscounted cash flows
	Carrying amount		Total		Within 1 year or on demand		1 - 2 years		More than 2 years
	$		$		$		$		$
At December 31, 2022
Non-derivative financial liabilities
Trade payables		7,291,133		7,291,133		7,291,133		—		—
Accrued expenses and other liabilities		15,668,734		15,668,734		15,611,421		57,313		—
Lease liabilities		6,646,163		7,308,540		3,022,367		1,678,615		2,607,558
Warrant liabilities		3,574,885		3,574,885		3,574,885		—		—
Liabilities for puttable financial instrument		17,138,905		17,138,905		17,138,905		—		—

		50,319,820		50,982,197		46,638,711		1,735,928		2,607,558


			Contractual undiscounted cash flows
	Carrying amount		Total		Within 1 year or on demand		1 - 2 years		More than 2 years
	$		$		$		$		$
At December 31, 2021
Non-derivative financial liabilities
Trade payables		9,979,726		9,979,726		9,979,726		—		—
Accrued expenses and other liabilities		36,280,298		36,280,298		36,280,298		—		—
Lease liabilities		5,267,210		5,981,170		1,921,466		1,743,456		2,316,248
Preference share liabilities - redemption amount		61,373,153		123,556,616		—		—		123,556,616

		112,900,387		175,797,810		48,181,490		1,743,456		125,872,864

Schedule of information about Level 3 fair value measurements

Liabilities for puttable financial instrument (Tables)

12 Months Ended

Dec. 31, 2022

Liabilities for puttable financial instrument [Abstract]

Schedule of liabilities for puttable financial instrument

The movement of the liabilities for puttable financial instrument during year ended December 31, 2022 are analyzed as follows:


	2022
	$
At January 1		—
Issuance of puttable financial instrument		17,138,905

At December 31		17,138,905

Reverse Recapitalization

12 Months Ended

Dec. 31, 2022

Reverse Recapitalization [Abstract]

Reverse Recapitalization

30	Reverse Recapitalization

As disclosed in note 1, the Reverse Recapitalization has been accounted for with reference to the principles of reverse acquisitions with PHCL being the accounting acquirer and Artisan the accounting acquiree. Accordingly, except for the capital structure, these financial statements have been presented as a continuation of the consolidated financial information of PHCL Group with:

•

the assets and liabilities of PHCL Group recognized and measured at their carrying amounts immediately prior to the Reverse Recapitalization;

•

the retained earnings and other equity balances of PHCL Group recognized at amounts immediately prior to the Reverse Recapitalization; and

•

the financial information for periods prior to the Reverse Recapitalization being that of PHCL Group.

As Artisan, the accounting acquiree, does not meet the definition of a business for the purposes of IFRS 3, the Reverse Recapitalization is determined to be an acquisition of the net assets of Artisan together with an equity-settled share-based payment which is regarded as an issuance of certain of the Company’s Class A ordinary shares in exchange for a stock exchange listing service. The stock exchange listing service has been recorded in profit or loss and measured as the excess of fair value of the Company’s Class A ordinary shares issued to acquire Artisan over the fair value of Artisan’s identifiable net assets acquired, with the amount expensed as incurred:


	$			$
Fair value of Artisan’s identifiable net assets acquired comprising					23,599,605
Prepayments		538,315
Cash and cash equivalent		30,363,822
Accrued expenses		(231,109	)
Warrants liabilities (note (i))		(6,186,423	)
Derivative liabilities (note (ii))		(885,000	)
Less: Fair value of consideration comprising:
14,523,244 Company’s Class A ordinary shares					(113,146,206	)

Share-based payment expense on listing					(89,546,601	)

Notes:

(i)

The warrants

liabilities

acquired include

those in relation to

the warrants issued by Artisan to Artisan’s public investors and Artisan LLC, the sponsor.

The holders of Artisan’s warrants (including public investors and the sponsor) received one warrant of the Company for each Artisan’s warrant, resulting in the issuance of 1,500,000 warrants of the Company (see note 26)

(ii)

Prior to the initial public offering of Artisan, institution investors (“FPA Investors”) agreed to purchase an aggregate of 6,000,000 Class A ordinary shares of Artisan and 1,500,000 redeemable warrants of Artisan at a price of $10 per Class A ordinary share and

⁄

warrant of Artisan in a private placement to close immediately prior to the closing of Artisan merging with one or more entities.

The

investment commitments from FPA Investors

represents

a derivative liability

of Artisan measured

at FVPL before the Initial Merger. As part of the Reverse Recapitalization, prior to the Initial Merger, the agreements with FPA Investors were amended such that FPA Investors committed to purchase a variable number of Class A ordinary shares and warrants of the Company at an aggregate price of $585,000 immediately prior to the closing of the Acquisition Merger. On May 18, 2022, the derivative liability was settled by issuing 6,000,000 Class A ordinary shares and 1,500,000 warrants of the Company to FPA Investors (see note 2

The Reverse Recapitalization has also involved the following transactions:

•

For additional capitalization, the Company issued 5,580,000 Class A ordinary shares to PIPE Investors on May 18, 2022 (see note 2

(b)), pursuant to the original subscription agreements dated on September 15, 2021 which was subsequently amended in 2022.

In the subscription agreements dated on September 15, 2021, PIPE Investors committed to purchase Class A ordinary shares of the Company at a price of $10 per share upon listing. The subscription agreements were amended on March 30, 2022 such that PIPE Investors committed to purchase a variable number of Class A ordinary shares of the Company at an aggregate price of $55,800,000 upon listing. The amendment of the subscription agreements with PIPE Investors results in recognition of a derivative liability measured at fair value through profit or loss, with a debit in equity. Upon completion of the Reverse Recapitalization, the derivative liability was settled by issuing 7,740,000 Class A ordinary shares of the Company to PIPE Investors.

•

Professional

services expenditure of $18,231,775

were

incurred to facilitate listing on NASDAQ

with

$3,529,904

and $14,701,871

recognized as administrative and other operating expenses in the profit or loss

for the years ended December 31, 2022 and 2021, respectively

Significant accounting policies - Additional Information (other than goodwill) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
IFRS Statement [Line Items]
Consideration refundable period from the date of delivery, services upfront	30 days
Revenue recognition, expected service period	5 years
Threshold period for registering purchase for warranty Circle HealthPod	30 days
Sample return period	6 months
Breakage revenue from unreturned kits	$ 230,107	$ 347,894	$ 3,325,906

Significant accounting policies (Policies)

12 Months Ended

Dec. 31, 2022

Significant accounting policies

Basis of consolidation

A	Basis of consolidation

(i)	Business combinations

The Group accounts for business combinations using the acquisition method when the acquired set of activities and assets meets the definition of a business and control is transferred to the Group. In determining whether a particular set of activities and assets is a business, the Group assesses whether the set of assets and activities acquired includes, at a minimum, an input and substantive process and whether the acquired set has the ability to produce outputs.

The Group has an option to apply a ‘concentration test’ that permits a simplified assessment of whether an acquired set of activities and assets is not a business. The optional concentration test is met if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets.

The consideration transferred in the acquisition is generally measured at fair value, as are the identifiable net assets acquired. Any goodwill that arises is tested annually for impairment. Any gain on a bargain purchase is recognized in profit or loss immediately. Transaction costs are expensed as incurred, except if related to the issue of debt or equity securities.

The consideration transferred does not include amounts related to the settlement of

pre-existing

relationships. Such amounts are generally recognized in profit or loss.

(ii)	Subsidiaries

Subsidiaries are entities controlled by the Group. The Group ‘controls’ an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases.

An investment in a subsidiary is consolidated into the consolidated financial statements from the date that control commences until the date that control ceases. Intra-group balances, transactions and cash flows and any unrealized profits arising from intra-group transactions are eliminated in full in preparing the consolidated financial statements. Unrealized losses resulting from intra-group transactions are eliminated in the same way as unrealized gains but only to the extent that there is no evidence of impairment.

(iii)

Non-controlling

interests

Non-controlling

interests are measured initially at their proportionate share of the acquiree’s identifiable net assets at the date of acquisition.

Changes in the Group’s interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions.

(iv)	Transactions eliminated on consolidation

Intra-group balances and transactions, and any unrealized income and expenses (except for foreign currency transaction gains or losses) arising from intra-group transactions, are eliminated. Unrealized losses are eliminated in the same way as unrealized gains, but only to the extent that there is no evidence of impairment.

(v)	Interests in equity-accounted investees

The Group’s interests in equity-accounted investees comprise interests in associates.

Associates are those entities in which the Group has significant influence, but not control or joint control, over the financial and operating policies. A joint venture is an arrangement in which the Group has joint control, whereby the Group has rights to the net assets of the arrangement, rather than rights to its assets and obligations for its liabilities.

Revenue and other income

C	Revenue and other income

Income is classified by the Group as revenue when it arises from the sale of goods or the provision of services in the ordinary course of the Group’s business.

Revenue is measured based on the amount of consideration to which the Group is expected to be entitled in exchange for transferring goods or services to a customer, excluding amounts collected on behalf of third parties. The Group recognizes revenue when (or as) it transfers control over a product or service to customer. An asset is transferred when (or as) the customer obtains control of the asset.

The Group transfers control of a good or service at a point in time unless one of the following overtime criteria is met:

(a)

the customer simultaneously receives and consumes the benefits provided as the Group performs;

(b)

the Group’s performance creates or enhances an asset that the customer controls as the asset is created or enhanced; or

(c)

the Group’s performance does not create an asset with an alternative use and the Group has an enforceable right to payment for performance completed to date.

The Group provides i) preventive services which are genetic testing services to individuals and corporates for their employees and customers; and ii) diagnostic services which are primarily

COVID-19

testing for individuals, corporates for their employees or customers, and governments for community testing. Additionally, from November 2021, the Group has officially launched iii) Circle HealthPod, which is a rapid detection health monitoring device along with

single-use

capsules that offers rapid

COVID-19

testing solutions for professional use and home use initially in Hong Kong.

The Group collects consideration for both types of services upfront, and such consideration received usually becomes

non-refundable

after 5 to 30 days from the date of delivery of the kits to the individuals or corporates, or the date of purchase. The upfront consideration received is initially recognized as deposit liabilities and subsequently reclassified to contract liabilities when the amount becomes

non-refundable.

Such amount does not include any variable consideration.

The Group determines that its sales contracts do not have a significant financing component when the upfront consideration becomes

non-refundable

as customers have discretion to decide when the tests are performed during the contract term.

(i)	Performance obligations

Generally, the Group fulfilled its performance obligations for preventive and diagnostic services at a point in time upon delivery of the testing results or reports to customers except for one category of the genetic testing kits under the preventive services which includes an additional distinct performance obligation being the subscription of free future updates to new features, reports and categories (collectively the “update services”).

The update services are considered distinct from the testing results or reports received by customers as those customers can benefit from the information provided in the testing results without the update services, the update services would not significantly modify the testing results, and there is not any significant interdependency between the testing results and the update services. Transfer of control for the testing results occurs when the testing results or reports are issued to customers and transfer of control for update services occurs over the expected service period which begins from the issuance of the testing results.

For genetic testing kits which contain the update services, the Group allocates revenue to the testing results and the update services on a relative standalone selling price basis. When estimating standalone prices, the Group considers all information that is reasonably available which includes market conditions, company-specific information about the customers, pricing strategies and practices, cost incurred to provide the service and industry pricing. The Group has estimated the standalone selling price of the update services based on the expected cost plus a margin and recognizes it over the expected service period of

five years. The expected service period was estimated based on the Group’s internal statistics on customers and expectation as to the period over which customers would continue to log in online to review initial reports and updates.

For sales of Circle HealthPod and

single-use

capsule sets, generally the Group considers it satisfies the associated performance obligation at the point in time when those products have been accepted by customers as, unlike the testing kits, customers do not need to return samples to the Group for further processing. The Group offers customers an unconditional right of return of unopened Circle HealthPod for cash for a period of 30 days from the date of acceptance. Revenue is recognized to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Accordingly, the Group reduces the revenues by an estimate of expected returns, determined based on the historical data, and recognizes a refund liability and an asset representing the right to recover the returned products.

Circle HealthPod also comes with a warranty for customers that register within 30

days of purchase, under which the Group will repair or replace a defective product within one year of purchase free-of-charge. The Group accounts for the warranty as an assurance warranty and recognizes an estimate of the associated costs as a liability at the time when the revenue on sale of Circle HealthPod is recognized. The amounts of expected returns and warranty in relation to Circle HealthPod are assessed as insignificant during the periods presented.

(ii)	Revenue breakage

Provision of preventive and diagnostic services require individuals to provide specimen samples to the Group before it can proceed with the necessary laboratory procedures. Sales contracts relating to testing kits sold directly to individuals normally require specimen samples to be sent back to the Group within 3 or 6 months (the “sample return period”) from the date of purchase depending on the jurisdictions in which the kits are purchased by customers. If these customers do not return their specimen samples within the sample return period, the Group has no further obligation to provide the service. Sales contracts relating to kits sold to corporates normally do not include specified sample return periods.

For certain

non-refundable

sale contracts, the Group does not have sufficient and relevant historical experience to form a reasonable expectation about the amount of breakage revenue to which the Group is expected to be entitled. This would be the case for certain preventive testing kits sold to corporates such as insurance companies that would ultimately be passed on to its end users at the corporates’ discretion, where there is no stated sample return period and the Group has no visibility as to whether and when the kits are distributed to end users. This would also be the case for certain diagnostic testing kits sold to individuals with respect to

COVID-19.

For these sales contracts, revenue is recognized at the earlier point in time of i) the relevant services are rendered and the testing results are issued; or ii) when the likelihood of end users returning their specimen samples becomes remote.

Otherwise, the Group generally has sufficient and relevant historical experience for other sales contracts such that the Group expects to be entitled to a breakage amount in relation to

non-refundable

and unexercised rights. For these sales contracts, the Group estimates and recognizes the expected breakage amount as revenue in proportion to the pattern of rights exercised by customers on a portfolio basis to the extent that it is considered highly probable that a significant reversal will not occur in the future.

The Group updates its breakage estimate regularly and if necessary, adjusts the deferred revenue balance accordingly. If actual return patterns vary from the estimate, actual breakage revenue may differ from the amounts recorded. The Group recognized breakage revenue from unreturned kits of

$230,107,

$347,894 and $3,325,906 for the years ended December 31, 2022, 2021 and 2020, respectively.

(iii)

Interest income

Interest income is recognized as it accrues using the effective interest method.

(iv)	Government subsidies

Government subsidies are recognized in the consolidated statement of financial position initially when there is reasonable assurance that they will be received and that the Group will comply with the conditions attaching to them. Grants that compensate the Group for expenses incurred are recognized as income in profit or loss on a systematic basis in the same periods in which the expenses are incurred. Grants that compensate the Group for the cost of an asset are deducted from the carrying amount of the asset and consequently are effectively recognized in profit or loss over the useful life of the asset by way of reduced depreciation expense.

Share capital

K	Share capital

(i)	Ordinary shares

Incremental costs directly attributable to the issue of ordinary shares are recognized as a deduction from equity.

(ii)	Preference shares

The Group’s redeemable preference shares are classified as financial liabilities, because they bear

non-discretionary

dividends and are redeemable in cash by the holders.

Non-discretionary

dividends thereon are recognized as interest expense in profit or loss as accrued.

Non-redeemable

preference shares are classified as equity, because they bear discretionary dividends, do not contain any obligations to deliver cash or other financial assets and do not require settlement in a variable number of the Group’s equity instruments. Discretionary dividends thereon are recognized as equity distributions on approval by the Company’s shareholders.

(iii)

Repurchase and reissue of ordinary shares (treasury shares)

When shares recognized as equity are repurchased, the amount of the consideration paid, which includes directly attributable costs, is recognized as a deduction from equity. Repurchased shares are classified as treasury shares and are presented in the treasury share reserve. When treasury shares are sold or reissued subsequently, the amount received is recognized as an increase in equity and the resulting surplus or deficit on the transaction is presented within share premium.

Warrant liabilities

12 Months Ended

Dec. 31, 2022

Warrant Liabilities [Abstract]

Warrant liabilities

26	Warrant liabilities

See accounting policies in note 36(J).

The Reverse Recapitalization

(see Note 30)

has included the issuance of 22,384,586 warrants. Each warrant entitles the holder to purchase one Class A ordinary share of the Company at an exercise price of $8.91 per whole share. The warrants are exercisable from May 18, 2022 and will expire on May 18, 2027.

The warrants are listed on NASDAQ under the trading symbol “PRENW” and are measured based on the market price.

Movement of the balance during the year ended December 31, 2022 is as follow:


	2022
	$
At January 1		—
Assumption of warrant upon the Reverse Recapitalization		6,186,423
Issuance of warrant		585,000
Change in fair value recognized in profit or loss		(3,196,538	)

At December 31		3,574,885

Short-term deposits and cash and cash equivalents - Additional Information (Details)	Dec. 31, 2022	Dec. 31, 2021
Short term deposits Line [Line Items]
Short term deposits weighted average interest rate point in time	5.21%	0.00%

Reverse Recapitalization (Tables)

12 Months Ended

Dec. 31, 2022

Disclosure Of Reverse Recapitalization [Line Items]

Summary of fair value of Artisan's identifiable net assets acquired


	$			$
Fair value of Artisan’s identifiable net assets acquired comprising					23,599,605
Prepayments		538,315
Cash and cash equivalent		30,363,822
Accrued expenses		(231,109	)
Warrants liabilities (note (i))		(6,186,423	)
Derivative liabilities (note (ii))		(885,000	)
Less: Fair value of consideration comprising:
14,523,244 Company’s Class A ordinary shares					(113,146,206	)

Share-based payment expense on listing					(89,546,601	)

Notes:

(i)

The warrants

liabilities

acquired include

those in relation to

the warrants issued by Artisan to Artisan’s public investors and Artisan LLC, the sponsor.

(ii)

⁄

warrant of Artisan in a private placement to close immediately prior to the closing of Artisan merging with one or more entities.

The

investment commitments from FPA Investors

represents

a derivative liability

of Artisan measured

Convertible securities - Movements of Debt (Details)	12 Months Ended
Convertible securities - Movements of Debt (Details)	Dec. 31, 2021 USD ($)
Convertible securities
Changes in fair value recognized in other reserve due to amendment of terms	$ 811,819
Converted to Series D preference shares of PHCL (note 25)	$ (50,193,319)

Liabilities for puttable financial instrument

12 Months Ended

Dec. 31, 2022

Liabilities for puttable financial instrument [Abstract]

Liabilities for puttable financial instrument

27	Liabilities for puttable financial instrument

See accounting policies in note 36(J).

On December 30, 2022, the Group acquired 74.39%

of the issued share capital of ACT Genomics. In connection with the ACT Acquisition, a puttable financial instrument had been granted under the shareholders’ agreements to the remaining shareholders of ACT (the “NCI of ACT”), which the Group has an obligation to buy the remaining shares from the NCI of ACT at specified price if the NCI of ACT exercises the option before the contract’s expiry date.

The puttable financial instrument is presented as a current financial liability in the consolidated financial statements due to a potential event could trigger within twelve months from the end of the reporting period.

The movement of the liabilities for puttable financial instrument during year ended December 31, 2022 are analyzed as follows:


	2022
	$
At January 1		—
Issuance of puttable financial instrument		17,138,905

At December 31		17,138,905

Financial instruments - Fair values and risk management

12 Months Ended

Dec. 31, 2022

Financial risk management and fair values of financial instruments

Financial instruments - Fair values and risk management

31	Financial instruments - Fair values and risk management

A.	Accounting classification and fair values


	Note		2022		2021
			$		$
Financial asset measured at fair value
Financial assets at FVPL		1 8		17,537,608		9,906,000

Financial assets at amortized cost
Trade receivables		1 7		41,691,913		47,041,538
Deposits and other receivables		15, 1 7		8,181,576		8,511,304
Amounts due from related companies				—		9,060
Cash and cash equivalents		19(b)		146,660,195		35,288,952

				196,533,684		90,850,854

Financial liabilities measured at fair value
Preference shares liabilities		2 5		—		486,404,770
Warrant liabilities		2 6		3,574,885		—

				3,574,885		486,404,770

Financial liabilities at amortized cost
Trade payables				7,291,133		9,979,726
Accrued expenses and other liabilities		20		15,668,734		36,280,298

Liabilities for puttable financial instrument		27		17,138,905		—
				40,098,772		46,260,024

The Group’s finance team is responsible for overseeing the valuation of the financial instruments, including the unlisted securities and the conversion feature embedded in the preference shares liabilities which are categorized into Level 3 of the fair value hierarchy. The team reports directly to the chief financial officer. Valuation results with analysis of changes in fair value measurement are prepared by the team with the assistance from external valuers where necessary and reviewed by the chief financial officer at each quarter end and annual reporting date. The valuation process is documented and updated where appropriate by the team and reviewed by the chief financial officer quarterly that coincides with the reporting dates.


			Fair value measurements at December 31, 2022 categorized into
	Fair value at December 31, 2022		Level 1		Level 2		Level 3
	$		$		$		$
Recurring fair value measurements
Asset:
Financial assets at FVPL:
- Unlisted securities		17,537,608		—		—		17,537,608

Liability:
Warrant liabilities		3,574,885		3,574,885		—		—


			Fair value measurements at December 31, 2021 categorized into
	Fair value at December 31, 2021		Level 1		Level 2		Level 3
	$		$		$		$
Recurring fair value measurements
Asset:
Financial assets at FVPL - Unlisted securities		9,906,000		—		—		9,906,000

Liability:
Preference shares liabilities - conversion feature		425,031,617		—		—		425,031,617

B.	Measurement of fair values

(i)	Valuation techniques and significant unobservable inputs

The following tables show the valuation techniques used in measuring Level 2 and Level 3 fair values for financial instruments in the statement of financial position, as well as the significant unobservable inputs used.

Financial instruments measured at fair value

(ii)	Transfers between Levels 1 and 2

There were no transfers from Level 2 to Level 1 in 2022 and no transfers in either direction in 2021.

(iii)

Level 3 recurring fair values

Sensitivity analysis

The following table indicates instantaneous changes in the Group’s loss if there is an increase/decrease in the significant unobservable inputs used in the valuation of preferred shares liabilities – conversion feature, assuming all other variables remain constant.


	December 31, 2021
Significant unobservable inputs	Increase/(decrease) in significant unobservable inputs %			Increase/(decrease) on the Group’s loss $
Risk-adjusted discount rate		5			(48,370,219	)
		(5	)		55,767,113
Discount for lack of marketability		5			(1,795,038	)
		(5	)		1,795,061
Expected volatility		5			84,785
		(5	)		(89,520	)

The movement of conversion feature of the preference shares liabilities during the year ended December 31, 2022 and 2021 are disclosed in note 25.

C.	Financial risk management

The Group has exposure to the following risks arising from financial instruments:

credit risk (see (C)(a));

liquidity risk (see (C)(b)); and

currency risk (see (C)(c)).

The Group’s exposure to these risks and the financial risk management policies and practices used by the Group to manage these risks are described below.

(a)	Credit risk

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in a financial loss to the Group. The Group’s credit risk is primarily attributable to trade receivables and cash and cash equivalents. The Group’s credit risk arising from cash and cash equivalents is limited because the counterparties are banks and financial institutions with good credit rating for which the Group considers to have low credit risk.

Trade receivables

The Group’s exposure to credit risk is influenced mainly by the individual characteristics of each customer. At December 31, 2022 and 2021, 56% and 46% of the total trade receivables were due from the Group’s largest customer, and 73% and 69% of the total trade receivables were due from the Group’s five largest customers, respectively.

Individual credit evaluations are performed on all customers requiring credit over a certain amount. These take into account the customer’s past payment history, financial position and other factors. Trade receivables are due within 30 to 60 days from the billing date. Normally, the Group does not obtain collateral from customers.

The Group measures loss allowances for trade receivables at an amount equal to lifetime ECLs. The Group allocates each individual customer to a credit risk grade based on a variety of data that is determined to be predictive of the risk of default and applying experienced credit judgement. Credit risk grades are defined using qualitative and quantitative factors that are indicative of risk of default. These factors vary depending on the nature of the exposure and the type of customer.

Each individual customer is allocated to a credit risk grade on initial recognition based on available information about the customer. Exposures are subject to ongoing monitoring, which may result in an exposure being moved to a different credit risk grade.

(a)	Credit risk (continued)

The Group then calculates an expected loss rate for each credit risk grade with reference to the weighted-average loss rate for each external credit rating published by external rating agencies. These rates are adjusted to reflect differences between economic conditions during the period over which the historic data has been collected, current conditions and the Group’s view of economic conditions over the expected lives of the receivables.

At December 31, 2022 and 2021, the overall expected loss rate was 0.13% and 0.80%, respectively, which reflected the settlement experience on the trade receivables.

Movement in the loss allowance account in respect of trade receivable during the years ended December 31, 2022 and 2021 is as follows:


	2022			2021
	$			$
At January 1		518,968			411,059
Net remeasurement of loss allowance		(136,493	)		110,114
Amounts written off		(33,808	)		—
Exchange differences		(20,118	)		(2,205	)

At December 31		328,549			518,968

(b)	Liquidity risk

The Group’s policy is to regularly monitor its liquidity requirements to ensure that it maintains sufficient reserves of cash to meet its liquidity requirements in the short and longer term.

The following table shows the remaining contractual maturities at the end of the reporting period of the Group’s

non-derivative


			Contractual undiscounted cash flows
	Carrying amount		Total		Within 1 year or on demand		1 - 2 years		More than 2 years
	$		$		$		$		$
At December 31, 2022
Non-derivative financial liabilities
Trade payables		7,291,133		7,291,133		7,291,133		—		—
Accrued expenses and other liabilities		15,668,734		15,668,734		15,611,421		57,313		—
Lease liabilities		6,646,163		7,308,540		3,022,367		1,678,615		2,607,558
Warrant liabilities		3,574,885		3,574,885		3,574,885		—		—
Liabilities for puttable financial instrument		17,138,905		17,138,905		17,138,905		—		—

		50,319,820		50,982,197		46,638,711		1,735,928		2,607,558


			Contractual undiscounted cash flows
	Carrying amount		Total		Within 1 year or on demand		1 - 2 years		More than 2 years
	$		$		$		$		$
At December 31, 2021
Non-derivative financial liabilities
Trade payables		9,979,726		9,979,726		9,979,726		—		—
Accrued expenses and other liabilities		36,280,298		36,280,298		36,280,298		—		—
Lease liabilities		5,267,210		5,981,170		1,921,466		1,743,456		2,316,248
Preference share liabilities - redemption amount		61,373,153		123,556,616		—		—		123,556,616

		112,900,387		175,797,810		48,181,490		1,743,456		125,872,864

(c)	Currency risk

The Company’s functional and presentation currency is USD. The Group is exposed to currency risk primarily through subsidiaries conducting their operations outside of Hong Kong with assets and liabilities denominated in other currencies, being primarily USD and Renminbi (“RMB”).

As the HKD is pegged to the USD, the Group considers the risk of movements in exchange rates between the HKD and the USD to be insignificant.

(i)	Exposure to currency risk

The following table details the Group’s exposure at the end of the reporting period to currency risk arising from recognized assets or liabilities denominated in a currency other than the functional currency of the entity to which they relate. For presentation purposes, the amounts of the exposure are shown in USD, translated using the spot rate at the year end date.


	December 31, 2022
	USD			RMB
	$			$
Trade receivables		79,220			—
Deposits and prepayments		2,972,471			872,455
Cash and cash equivalents		12,225,385			14
Trade payables		(3,984,494	)		(2,029,309	)
Accrued expenses and other liabilities		(3,741,359	)		—

Net exposure to currency risk		7,551,223			(1,156,840	)


	December 31, 2021
	USD			RMB
	$			$

Trade receivables		373,889			—
Deposits and prepayments		3,899,656			4,500,406
Cash and cash equivalents		1,231,648			14
Trade payables		(2,112,494	)		(6,113,239	)
Accrued expenses and other liabilities		(11,420,246	)		(107	)

Net exposure to currency risk		(8,027,547	)		(1,612,926	)

(ii)	Sensitivity analysis

The following table indicates the instantaneous change in the Group’s loss after tax (and accumulated losses) that would arise if foreign exchange rates to which the Group has significant exposure at the end of the reporting period had changed at that date, assuming all other risk variables remained constant. In this respect, it is assumed that the pegged rate between the Hong Kong dollar and the United States dollar would be materially unaffected by any changes in movement in value of the United States dollar against other currencies.


	2022						2021
	Increase/ (decrease) in foreign exchange rates			Effect on loss after tax and accumulated losses			Increase/ (decrease) in foreign exchange rates			Effect on loss after tax and accumulated losses
	%			$			%			$

USD		1			(63,061	)		1			67,269
		(1	)		63,061			(1	)		(67,269	)
RMB		5			48,298			1			13,468
		(5	)		(48,298	)		(1	)		(13,468	)

Convertible securities (Tables)

12 Months Ended

Dec. 31, 2022

Convertible securities

Schedule of convertible securities

Movement of the balance during the year ended December 31, 2021 was as follow:


	$
At January 1, 2021		15,346,113
Proceeds from issuance of convertible securities		4,980,718
Changes in fair value recognized in profit or loss		29,054,669
Changes in fair value recognized in other reserve due to amendment of terms		811,819
Converted to Series D preference shares of PHCL (note 25)		(50,193,319	)

At December 31, 2021, January 1, 2022 and December 31, 2022		—

Significant accounting policies (Tables)

12 Months Ended

Dec. 31, 2022

Significant accounting policies

Schedule of estimated useful lives of property and equipment


–	Properties leased for own use	Over the unexpired lease period

–	Office equipment leased for own use	Over the unexpired lease period

–	Leasehold improvements	Shorter period of the lease term or the useful life

–	Fixtures and furniture	3 - 5 years

–	Office and lab equipment	3 - 5 years

–	Computer equipment	3 years

–	Motor vehicles	3 - 5 years

–	Manufacturing equipment	3 - 5 years

Schedule of estimated useful lives of intangible assets


– Website and mobile apps		2 years
– Trademark and technology		10 - 20 years
– Products development cost		3 years
– Computer software		3 years
– Customer relationship		10 years

Loss before taxation

12 Months Ended

Dec. 31, 2022

Loss before taxation

Loss before taxation

8	Loss before taxation

Loss before taxation is arrived at after charging:

(a)	Other finance costs

See accounting policies in notes 36(E) and (J).


	2022		2021		2020
	$		$		$
Interest expenses on lease liabilities (notes 11(a) and 23(b))		244,085		205,915		49,400
Interest expenses on trade financing (note 23(b))		172,978		—		—
Imputed interest on deferred consideration		—		22,235		9,513
Changes in the carrying amount of preference shares liabilities (note 25)		3,752,758		5,009,847		—
Other interest expenses		28,363		33		654

		4,198,184		5,238,030		59,567

(b)	Staff costs


	2022		2021		2020
	$		$		$
Salaries, wages and other benefits		109,644,199		76,622,503		16,019,896
Contributions to defined contribution retirement plan		861,863		562,427		219,440
Equity-settled share-based payment expenses		31,339,185		22,141,614		1,229,312

		141,845,247		99,326,544		17,468,648

Represented by:
Direct costs		63,647,052		48,414,622		5,377,536
Selling and distribution expenses		1,782,149		1,299,320		675,418
Research and development expenses		13,404,496		6,943,308		2,056,653
Administrative and other operating expenses		63,011,550		42,669,294		9,359,041

Total staff costs		141,845,247		99,326,544		17,468,648

(c)	Restructuring costs in relation to diagnostic business

	2022		2021		2020
	$		$		$
Restructuring costs in relation to diagnostic business
- impairment of intangible assets (note 12)		19,109,580		—		—
- impairment of goodwill (note 13)		3,272,253		—		—
- impairment losses on property, plant and equipment (note 11)		4,447,610		—		—
- write-off of prepayment		3,549,298		—		—

		30,378,741		—		—

During the year ended December 31, 2022, the Group has undertaken a restructuring of the diagnostic business. As a result, an impairment assessment of the CGU Prevention EMEA and CGU Diagnostics EMEA has been performed which the recoverable amounts of the CGUs were less than the carrying amounts of the CGUs. Impairment/write-off on certain assets included in the respective CGUs, namely intangible assets, goodwill, property, plant and equipment and prepayment has been recognized in the profit or loss. In addition, the Group recorded a write-off of prepayment in relation to the diagnostics business.

(d)	Other items


	2022		2021		2020
	$		$		$
Cost of inventories (note 16)		57,442,036		52,701,330		10,412,753
Depreciation of (note 11)
- property, plant and equipment #		3,899,721		2,745,549		708,637
- right-of-use assets #		2,087,167		1,542,566		583,835
Amortization of intangible assets # (note 12)		1,556,091		3,058,527		1,133,564
Write-off on property, plant and equipment		268,226		476,431		—
Auditor’s remuneration		1,439,617		1,221,439		566,553
Miscellaneous laboratory charges		268		13,953		12,892

# Represented by:
Direct costs		1,892,036		1,182,134		462,809
Research and development expenses		340,690		145,876		63,162
Administrative and other operating expenses		5,310,253		6,018,632		1,900,065

Total depreciation and amortization charges		7,542,979		7,346,642		2,426,036

Warrant liabilities - Summary of Movement in Warrant Liabilities (Details)	12 Months Ended
	Dec. 31, 2022 USD ($)
Disclosure of warranty liabilities [line items]
Assumption of warrant upon the Reverse Recapitalization	$ 6,186,423

Loss before taxation - Other items (Details) - USD ($)	12 Months Ended
Loss before taxation - Other items (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Depreciation of (note 11)
Miscellaneous laboratory charges	$ 268	$ 13,953	$ 12,892

Loss before taxation (Tables)

12 Months Ended

Dec. 31, 2022

Loss before taxation

Schedule of expenses by nature

(a)	Other finance costs

See accounting policies in notes 36(E) and (J).


	2022		2021		2020
	$		$		$
Interest expenses on lease liabilities (notes 11(a) and 23(b))		244,085		205,915		49,400
Interest expenses on trade financing (note 23(b))		172,978		—		—
Imputed interest on deferred consideration		—		22,235		9,513
Changes in the carrying amount of preference shares liabilities (note 25)		3,752,758		5,009,847		—
Other interest expenses		28,363		33		654

		4,198,184		5,238,030		59,567

(b)	Staff costs


	2022		2021		2020
	$		$		$
Salaries, wages and other benefits		109,644,199		76,622,503		16,019,896
Contributions to defined contribution retirement plan		861,863		562,427		219,440
Equity-settled share-based payment expenses		31,339,185		22,141,614		1,229,312

		141,845,247		99,326,544		17,468,648

Represented by:
Direct costs		63,647,052		48,414,622		5,377,536
Selling and distribution expenses		1,782,149		1,299,320		675,418
Research and development expenses		13,404,496		6,943,308		2,056,653
Administrative and other operating expenses		63,011,550		42,669,294		9,359,041

Total staff costs		141,845,247		99,326,544		17,468,648

(c)	Restructuring costs in relation to diagnostic business

	2022		2021		2020
	$		$		$
Restructuring costs in relation to diagnostic business
- impairment of intangible assets (note 12)		19,109,580		—		—
- impairment of goodwill (note 13)		3,272,253		—		—
- impairment losses on property, plant and equipment (note 11)		4,447,610		—		—
- write-off of prepayment		3,549,298		—		—

		30,378,741		—		—

(d)	Other items


	2022		2021		2020
	$		$		$
Cost of inventories (note 16)		57,442,036		52,701,330		10,412,753
Depreciation of (note 11)
- property, plant and equipment #		3,899,721		2,745,549		708,637
- right-of-use assets #		2,087,167		1,542,566		583,835
Amortization of intangible assets # (note 12)		1,556,091		3,058,527		1,133,564
Write-off on property, plant and equipment		268,226		476,431		—
Auditor’s remuneration		1,439,617		1,221,439		566,553
Miscellaneous laboratory charges		268		13,953		12,892

# Represented by:
Direct costs		1,892,036		1,182,134		462,809
Research and development expenses		340,690		145,876		63,162
Administrative and other operating expenses		5,310,253		6,018,632		1,900,065

Total depreciation and amortization charges		7,542,979		7,346,642		2,426,036

Reverse Recapitalization - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Mar. 30, 2022	Sep. 15, 2021
Disclosure Of Reverse Recapitalization [Line Items]
Administrative and Other Operating Expenses	$ 96,063,312	$ 83,991,413	$ 16,616,462
NASDAQ Stock Market [Member]
Disclosure Of Reverse Recapitalization [Line Items]
Administrative and Other Operating Expenses	$ 3,529,904	$ 14,701,871
Class A ordinary shares [Member]
Disclosure Of Reverse Recapitalization [Line Items]
Sale of stock price per share	$ 10			$ 55,800,000	$ 10
Shares issued upon conversion	6,000,000				7,740,000

Accrued expenses and other liabilities (Tables)

12 Months Ended

Dec. 31, 2022

Accrued expenses and other current liabilities

Schedule of accrued expenses and other liabilities


	2022 $		2021 $
Current
Accrued staff costs		1,405,316		1,763,099
Accrued expenses		2,949,038		12,131,214
Accrued professional fee		4,432,425		11,877,996
Value added tax payable		58,093		1,893,190
Deposit liabilities		328,559		2,690,842
Consideration payable in relation to the ACT Acquisition (note)		958,224		—
Other payables and accruals		5,479,766		5,923,957

		15,611,421		36,280,298
Non-current
Other non-current liabilities		949,701		—

		16,561,122		36,280,298

Related parties

12 Months Ended

Dec. 31, 2022

Related party transactions

Related parties

34	Related parties

Apart from balances and transactions disclosed elsewhere in these consolidated financial statements, the Group has also entered into the following related party transactions under the normal course of the Group’s business:

(a)	Transactions with other related parties


	2022		2021		2020
	$		$		$
Sales to a shareholder		—		—		16,950
Purchase from a joint venture		—		53,981		21,119
Services provided by a company with control from a director of the Company		30,630		90,353		—
Legal and professional fee paid on behalf of related companies		—		9,060		—

(b)	Acquisition of a subsidiary

On July 1, 2021, Prenetics EMEA Limited, an indirectly wholly-owned subsidiary of the Company, entered into a share purchase agreement to

acquire 100% equity interest of DNAFit Africa (Pty) Limited from its sole shareholder, who is a staff of Prenetics EMEA Limited, at a cash consideration of ZAR1,000 (approximately equivalent to $65), resulting in a gain on bargain purchase of $117,238.

Upon the completion of the acquisition, DNAFit Africa (Pty) Limited becomes a direct wholly-owned subsidiary of the Prenetics EMEA Limited.

(c)	Key management personnel compensation

Key management personnel compensation comprised as following.


	2022 $		2021 $		2020 $
Directors’ fees		261,110		—		—
Salaries, wages and other benefits		24,549,012		2,281,701		2,206,494
Contributions to defined contribution retirement plan		17,538		15,643		4,615
Equity-settled share-based payment expenses (note)		30,284,686		21,500,167		913,111

		55,112,346		23,797,511		3,124,220

Note:

The balances are non-cash transactions for the reporting period. Details of the recognition and the fair value determination are included in note 29.

Label

Element

Value

Deferred Consideration Payable Current

pre_DeferredConsiderationPayableCurrent

$ 958,224

Period of Revenue to be Recognized

pre_PeriodOfRevenueToBeRecognized

1 year

Additional Recognition From Business Acquisition , goodwill

pre_AdditionalRecognitionFromBusinessAcquisitionGoodwill

$ 33,800,276

Written Back of Disposals, Property, Plant and Equipment

pre_WrittenBackOfDisposalsPropertyPlantAndEquipment

(137,959)

Written Back of Disposals, Property, Plant and Equipment

pre_WrittenBackOfDisposalsPropertyPlantAndEquipment

Written Back of Disposals, Property, Plant and Equipment

pre_WrittenBackOfDisposalsPropertyPlantAndEquipment

(39,020)

Written Back of Disposals, Property, Plant and Equipment

pre_WrittenBackOfDisposalsPropertyPlantAndEquipment

(39,635)

Written Back of Disposals, Property, Plant and Equipment

pre_WrittenBackOfDisposalsPropertyPlantAndEquipment

(6,735)

Written Back of Disposals, Property, Plant and Equipment

pre_WrittenBackOfDisposalsPropertyPlantAndEquipment

(223,349)

Written Back of Disposals, Property, Plant and Equipment

pre_WrittenBackOfDisposalsPropertyPlantAndEquipment

(24,776)

Written Back of Disposals, Property, Plant and Equipment

pre_WrittenBackOfDisposalsPropertyPlantAndEquipment

(285,044)

Written Back of Disposals, Property, Plant and Equipment

pre_WrittenBackOfDisposalsPropertyPlantAndEquipment

(41,151)

Written Back of Disposals, Property, Plant and Equipment

pre_WrittenBackOfDisposalsPropertyPlantAndEquipment

(35,574)

Written Back of Disposals, Property, Plant and Equipment

pre_WrittenBackOfDisposalsPropertyPlantAndEquipment

(386,545)

Deposit Liabilities, Current

pre_DepositLiabilitiesCurrent

328,559

Deposit Liabilities, Current

pre_DepositLiabilitiesCurrent

2,690,842

Increase (Decrease) through Vesting of Share-Based Payment Transactions

pre_IncreaseDecreaseThroughVestingOfShareBasedPaymentTransactions

48,622

Increase (Decrease) through Vesting of Share-Based Payment Transactions

pre_IncreaseDecreaseThroughVestingOfShareBasedPaymentTransactions

48,622

Increase (Decrease) through Vesting of Share-Based Payment Transactions

pre_IncreaseDecreaseThroughVestingOfShareBasedPaymentTransactions

48,622

Increase (Decrease) through Vesting of Share-Based Payment Transactions

pre_IncreaseDecreaseThroughVestingOfShareBasedPaymentTransactions

4,517

Increase (Decrease) through Vesting of Share-Based Payment Transactions

pre_IncreaseDecreaseThroughVestingOfShareBasedPaymentTransactions

4,517

Increase (Decrease) through Vesting of Share-Based Payment Transactions

pre_IncreaseDecreaseThroughVestingOfShareBasedPaymentTransactions

4,517

Increase (Decrease) through Vesting of Share-Based Payment Transactions

pre_IncreaseDecreaseThroughVestingOfShareBasedPaymentTransactions

785

Increase (Decrease) through Vesting of Share-Based Payment Transactions

pre_IncreaseDecreaseThroughVestingOfShareBasedPaymentTransactions

116,079

Increase (Decrease) through Vesting of Share-Based Payment Transactions

pre_IncreaseDecreaseThroughVestingOfShareBasedPaymentTransactions

116,864

Increase (Decrease) through Vesting of Share-Based Payment Transactions

pre_IncreaseDecreaseThroughVestingOfShareBasedPaymentTransactions

$ 116,864

Number Of Instruments Or Interests Issued Or Issuables

pre_NumberOfInstrumentsOrInterestsIssuedOrIssuables

388,216

Number Of Instruments Or Interests Issued Or Issuables

pre_NumberOfInstrumentsOrInterestsIssuedOrIssuables

1,652,248

Tax effect of Temporary Difference Not Recognized

pre_TaxEffectOfTemporaryDifferenceNotRecognized

$ 73,833

Tax Losses Utilized

pre_TaxLossesUtilized

62,586,553

Tax Losses Utilized

pre_TaxLossesUtilized

Tax Losses Utilized

pre_TaxLossesUtilized

3,050,828

Tax Losses Utilized

pre_TaxLossesUtilized

893,511

Tax Losses Utilized

pre_TaxLossesUtilized

Tax Losses Utilized

pre_TaxLossesUtilized

14,362,136

Tax Losses Utilized

pre_TaxLossesUtilized

Tax Losses Utilized

pre_TaxLossesUtilized

25,085,050

Tax Losses Utilized

pre_TaxLossesUtilized

Tax Losses Utilized

pre_TaxLossesUtilized

22,245,856

Tax Losses Utilized

pre_TaxLossesUtilized

Increase (Decrease) Through Changes In Fair Values Of Preference Shares Liabilities, Liabilities Arising From Financing Activities

pre_IncreaseDecreaseThroughChangesInFairValuesOfPreferenceSharesLiabilitiesLiabilitiesArisingFromFinancingActivities

125,398,798

Increase (Decrease) Through Changes In Fair Values Of Preference Shares Liabilities, Liabilities Arising From Financing Activities

pre_IncreaseDecreaseThroughChangesInFairValuesOfPreferenceSharesLiabilitiesLiabilitiesArisingFromFinancingActivities

125,398,798

Increase (Decrease) Through Changes In Fair Values Of Preference Shares Liabilities, Liabilities Arising From Financing Activities

pre_IncreaseDecreaseThroughChangesInFairValuesOfPreferenceSharesLiabilitiesLiabilitiesArisingFromFinancingActivities

60,091,353

Increase (Decrease) Through Changes In Fair Values Of Preference Shares Liabilities, Liabilities Arising From Financing Activities

pre_IncreaseDecreaseThroughChangesInFairValuesOfPreferenceSharesLiabilitiesLiabilitiesArisingFromFinancingActivities

60,091,353

Tax effect of Previously Unrecognized Temporary Differences Recognized in Current Period

pre_TaxEffectOfPreviouslyUnrecognizedTemporaryDifferencesRecognizedInCurrentPeriod

263,272

Tax effect of Previously Unrecognized Temporary Differences Recognized in Current Period

pre_TaxEffectOfPreviouslyUnrecognizedTemporaryDifferencesRecognizedInCurrentPeriod

(360,922)

Tax effect of Previously Unrecognized Temporary Differences Recognized in Current Period

pre_TaxEffectOfPreviouslyUnrecognizedTemporaryDifferencesRecognizedInCurrentPeriod

1,957,229

Gain (loss) Exchange Difference on Deferred Tax Recognised

pre_GainLossExchangeDifferenceOnDeferredTaxRecognised

12,727

Gain (loss) Exchange Difference on Deferred Tax Recognised

pre_GainLossExchangeDifferenceOnDeferredTaxRecognised

(39,709)

Gain (loss) Exchange Difference on Deferred Tax Recognised

pre_GainLossExchangeDifferenceOnDeferredTaxRecognised

33,057

Gain (loss) Exchange Difference on Deferred Tax Recognised

pre_GainLossExchangeDifferenceOnDeferredTaxRecognised

6,075

Gain (loss) Exchange Difference on Deferred Tax Recognised

pre_GainLossExchangeDifferenceOnDeferredTaxRecognised

(3,839)

Gain (loss) Exchange Difference on Deferred Tax Recognised

pre_GainLossExchangeDifferenceOnDeferredTaxRecognised

9,710

Gain (loss) Exchange Difference on Deferred Tax Recognised

pre_GainLossExchangeDifferenceOnDeferredTaxRecognised

(4,968)

Gain (loss) Exchange Difference on Deferred Tax Recognised

pre_GainLossExchangeDifferenceOnDeferredTaxRecognised

903

Gain (loss) Exchange Difference on Deferred Tax Recognised

pre_GainLossExchangeDifferenceOnDeferredTaxRecognised

(38,448)

Gain (loss) Exchange Difference on Deferred Tax Recognised

pre_GainLossExchangeDifferenceOnDeferredTaxRecognised

2,489

Gain (loss) Exchange Difference on Deferred Tax Recognised

pre_GainLossExchangeDifferenceOnDeferredTaxRecognised

(35,959)

Increase (Decrease) Through Reclassification From Equity To Liabilities, Liabilities Arising From Financing Activities

pre_IncreaseDecreaseThroughReclassificationFromEquityToLiabilitiesLiabilitiesArisingFromFinancingActivities

279,832,806

Increase (Decrease) Through Reclassification From Equity To Liabilities, Liabilities Arising From Financing Activities

pre_IncreaseDecreaseThroughReclassificationFromEquityToLiabilitiesLiabilitiesArisingFromFinancingActivities

279,832,806

Increase (Decrease) Through Reclassification From Equity To Liabilities, Liabilities Arising From Financing Activities

pre_IncreaseDecreaseThroughReclassificationFromEquityToLiabilitiesLiabilitiesArisingFromFinancingActivities

(550,248,881)

Increase (Decrease) Through Reclassification From Equity To Liabilities, Liabilities Arising From Financing Activities

pre_IncreaseDecreaseThroughReclassificationFromEquityToLiabilitiesLiabilitiesArisingFromFinancingActivities

(550,248,881)

Accrued Expenses, Current

pre_AccruedExpensesCurrent

2,949,038

Accrued Expenses, Current

pre_AccruedExpensesCurrent

$ 12,131,214

Disclosure Of Detailed Information About Deferred Tax Liability Asset Explanatory [Table Text Block]

pre_DisclosureOfDetailedInformationAboutDeferredTaxLiabilityAssetExplanatoryTableTextBlock


	2022			2021
	$			$
Represented by:
Deferred tax assets		(243,449	)		(79,702	)
Deferred tax liabilities		3,185,440			659,498

		2,941,991			579,796

Increase (Decrease) Through Adjustments From Restructuring, Equity

pre_IncreaseDecreaseThroughAdjustmentsFromRestructuringEquity

$ (15,348,379)

Increase (Decrease) Through Adjustments From Restructuring, Equity

pre_IncreaseDecreaseThroughAdjustmentsFromRestructuringEquity

15,348,379

Tax effect Utilization of Previously Unrecognized Tax Loss

pre_TaxEffectUtilizationOfPreviouslyUnrecognizedTaxLoss

579,657

Tax effect Utilization of Previously Unrecognized Tax Loss

pre_TaxEffectUtilizationOfPreviouslyUnrecognizedTaxLoss

692,350

Increase (Decrease) Through Changes In Carrying Value Of Preference Shares Liabilities, Liabilities Arising From Financing Activities

pre_IncreaseDecreaseThroughChangesInCarryingValueOfPreferenceSharesLiabilitiesLiabilitiesArisingFromFinancingActivities

(3,752,758)

Increase (Decrease) Through Changes In Carrying Value Of Preference Shares Liabilities, Liabilities Arising From Financing Activities

pre_IncreaseDecreaseThroughChangesInCarryingValueOfPreferenceSharesLiabilitiesLiabilitiesArisingFromFinancingActivities

(5,009,847)

Increase (Decrease) Through Changes In Carrying Value Of Preference Shares Liabilities, Liabilities Arising From Financing Activities

pre_IncreaseDecreaseThroughChangesInCarryingValueOfPreferenceSharesLiabilitiesLiabilitiesArisingFromFinancingActivities

(5,009,847)

Increase (Decrease) Through Changes In Carrying Value Of Preference Shares Liabilities, Liabilities Arising From Financing Activities

pre_IncreaseDecreaseThroughChangesInCarryingValueOfPreferenceSharesLiabilitiesLiabilitiesArisingFromFinancingActivities

(3,752,758)

Gains (Losses) On Change In Fair Value Of Financial Assets At Fair Value Through Profit Or Loss

pre_GainsLossesOnChangeInFairValueOfFinancialAssetsAtFairValueThroughProfitOrLoss

(9,363,495)

Gains (Losses) On Change In Fair Value Of Financial Assets At Fair Value Through Profit Or Loss

pre_GainsLossesOnChangeInFairValueOfFinancialAssetsAtFairValueThroughProfitOrLoss

(94,000)

Payments of Capital Element of Lease liabilities, Classified as Financing Activities

pre_PaymentsOfCapitalElementOfLeaseLiabilitiesClassifiedAsFinancingActivities

1,877,896

Payments of Capital Element of Lease liabilities, Classified as Financing Activities

pre_PaymentsOfCapitalElementOfLeaseLiabilitiesClassifiedAsFinancingActivities

1,299,031

Payments of Capital Element of Lease liabilities, Classified as Financing Activities

pre_PaymentsOfCapitalElementOfLeaseLiabilitiesClassifiedAsFinancingActivities

610,926

Written Back on Disposal Intangible Assets Other Than Goodwill

pre_WrittenBackOnDisposalIntangibleAssetsOtherThanGoodwill

(83,549)

Written Back on Disposal Intangible Assets Other Than Goodwill

pre_WrittenBackOnDisposalIntangibleAssetsOtherThanGoodwill

(3,131,244)

Written Back on Disposal Intangible Assets Other Than Goodwill

pre_WrittenBackOnDisposalIntangibleAssetsOtherThanGoodwill

(3,214,793)

Increase (Decrease) Through Changes In Other Reserve, Liabilities Arising From Financing Activities

pre_IncreaseDecreaseThroughChangesInOtherReserveLiabilitiesArisingFromFinancingActivities

811,819

Increase (Decrease) Through Changes In Other Reserve, Liabilities Arising From Financing Activities

pre_IncreaseDecreaseThroughChangesInOtherReserveLiabilitiesArisingFromFinancingActivities

811,819

Warrant Liability Undiscounted Cash Flows

pre_WarrantLiabilityUndiscountedCashFlows

3,574,885

Warrant Liability Undiscounted Cash Flows

pre_WarrantLiabilityUndiscountedCashFlows

$ 3,574,885

Average Revenue Growth Rate Used To Extrapolate Cash Flow Projections

pre_AverageRevenueGrowthRateUsedToExtrapolateCashFlowProjections

31.10%

Average Revenue Growth Rate Used To Extrapolate Cash Flow Projections

pre_AverageRevenueGrowthRateUsedToExtrapolateCashFlowProjections

18.30%

Average Revenue Growth Rate Used To Extrapolate Cash Flow Projections

pre_AverageRevenueGrowthRateUsedToExtrapolateCashFlowProjections

25.10%

Average Revenue Growth Rate Used To Extrapolate Cash Flow Projections

pre_AverageRevenueGrowthRateUsedToExtrapolateCashFlowProjections

24.40%

Average Revenue Growth Rate Used To Extrapolate Cash Flow Projections

pre_AverageRevenueGrowthRateUsedToExtrapolateCashFlowProjections

18.40%

Increase Through Conversion Of Convertible Securities, Liabilities Arising From Financing Activities

pre_IncreaseThroughConversionOfConvertibleSecuritiesLiabilitiesArisingFromFinancingActivities

$ (50,193,319)

Increase Through Conversion Of Convertible Securities, Liabilities Arising From Financing Activities

pre_IncreaseThroughConversionOfConvertibleSecuritiesLiabilitiesArisingFromFinancingActivities

50,193,319

Decrease Through Vesting Of Shares, Liabilities Arising From Financing Activities

pre_DecreaseThroughVestingOfSharesLiabilitiesArisingFromFinancingActivities

(4,517)

Decrease Through Vesting Of Shares, Liabilities Arising From Financing Activities

pre_DecreaseThroughVestingOfSharesLiabilitiesArisingFromFinancingActivities

$ (4,517)

Cash Flow Projections Period

pre_CashFlowProjectionsPeriod

10 years

Gains (Losses) On Change In Fair Value Of Financial Liabilities

pre_GainsLossesOnChangeInFairValueOfFinancialLiabilities

$ (60,091,353)

Gains (Losses) On Change In Fair Value Of Financial Liabilities

pre_GainsLossesOnChangeInFairValueOfFinancialLiabilities

(125,398,798)

Ifrs Accrued Professional Fees, Current

pre_IfrsAccruedProfessionalFeesCurrent

4,432,425

Ifrs Accrued Professional Fees, Current

pre_IfrsAccruedProfessionalFeesCurrent

11,877,996

Preferred Stock Redemption Amount, Undiscounted Cash Flows

pre_PreferredStockRedemptionAmountUndiscountedCashFlows

123,556,616

Preferred Stock Redemption Amount, Undiscounted Cash Flows

pre_PreferredStockRedemptionAmountUndiscountedCashFlows

123,556,616

Decrease Through Payment Of Capital Element Lease Liabilities, Liabilities Arising from Financing Activities

pre_DecreaseThroughPaymentOfCapitalElementLeaseLiabilitiesLiabilitiesArisingFromFinancingActivities

1,299,031

Decrease Through Payment Of Capital Element Lease Liabilities, Liabilities Arising from Financing Activities

pre_DecreaseThroughPaymentOfCapitalElementLeaseLiabilitiesLiabilitiesArisingFromFinancingActivities

1,299,031

Decrease Through Payment Of Capital Element Lease Liabilities, Liabilities Arising from Financing Activities

pre_DecreaseThroughPaymentOfCapitalElementLeaseLiabilitiesLiabilitiesArisingFromFinancingActivities

1,834,272

Decrease Through Payment Of Capital Element Lease Liabilities, Liabilities Arising from Financing Activities

pre_DecreaseThroughPaymentOfCapitalElementLeaseLiabilitiesLiabilitiesArisingFromFinancingActivities

1,834,272

Authorised Share Capital

pre_AuthorisedShareCapital

50,000

Authorised Share Capital

pre_AuthorisedShareCapital

50,000

Decrease Through Payment Of Interest Element Of Lease Liabilities, Liabilities Arising from Financing Activities

pre_DecreaseThroughPaymentOfInterestElementOfLeaseLiabilitiesLiabilitiesArisingFromFinancingActivities

205,915

Decrease Through Payment Of Interest Element Of Lease Liabilities, Liabilities Arising from Financing Activities

pre_DecreaseThroughPaymentOfInterestElementOfLeaseLiabilitiesLiabilitiesArisingFromFinancingActivities

205,915

Decrease Through Payment Of Interest Element Of Lease Liabilities, Liabilities Arising from Financing Activities

pre_DecreaseThroughPaymentOfInterestElementOfLeaseLiabilitiesLiabilitiesArisingFromFinancingActivities

244,085

Decrease Through Payment Of Interest Element Of Lease Liabilities, Liabilities Arising from Financing Activities

pre_DecreaseThroughPaymentOfInterestElementOfLeaseLiabilitiesLiabilitiesArisingFromFinancingActivities

244,085

Gains (losses) on change in fair value of warrant liabilities

pre_GainsLossesOnChangeInFairValueOfWarrantLiabilities

$ 3,196,538

Disclosure Of Detailed Information Expiry Date Of Cumulative Tax Losses Explanatory [Table Text Block]

pre_DisclosureOfDetailedInformationExpiryDateOfCumulativeTaxLossesExplanatoryTableTextBlock

The expiry dates of the cumulative tax losses are as follows:


	2022		2021
	$		$
Within 1 year		893,511		—
Over 1 year but within 5 years		14,362,136		—
Over 5 years but within 10 years		25,085,050		—
Do not expire under the relevant tax legislations		22,245,856		—

		62,586,553		—

IFRS Antidilutive Securities Excluded From Computation Of Earnings Per Share Amounts

pre_IfrsAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmounts

20,025,247

Proceeds From Trade Financing Liabilities Arising From Financing Activities

pre_ProceedsFromTradeFinancingLiabilitiesArisingFromFinancingActivities

$ 21,677,075

Proceeds From Trade Financing Liabilities Arising From Financing Activities

pre_ProceedsFromTradeFinancingLiabilitiesArisingFromFinancingActivities

21,677,075

Proceeds From Trade Financing Liabilities Arising From Financing Activities

pre_ProceedsFromTradeFinancingLiabilitiesArisingFromFinancingActivities

21,677,075

Repayments Of Trade Financing Liabilities Arising From Financing Activities

pre_RepaymentsOfTradeFinancingLiabilitiesArisingFromFinancingActivities

21,677,075

Repayments Of Trade Financing Liabilities Arising From Financing Activities

pre_RepaymentsOfTradeFinancingLiabilitiesArisingFromFinancingActivities

(21,677,075)

Repayments Of Trade Financing Liabilities Arising From Financing Activities

pre_RepaymentsOfTradeFinancingLiabilitiesArisingFromFinancingActivities

(21,677,075)

Adjustments for Increase (Decrease) in Accrued Expenses and Other Current Liabilities

pre_AdjustmentsForIncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities

(24,390,581)

Adjustments for Increase (Decrease) in Accrued Expenses and Other Current Liabilities

pre_AdjustmentsForIncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities

27,350,803

Adjustments for Increase (Decrease) in Accrued Expenses and Other Current Liabilities

pre_AdjustmentsForIncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities

5,962,060

Adjustments for Decrease (Increase) in Other Noncurrent Assets

pre_AdjustmentsForDecreaseIncreaseInOtherNoncurrentAssets

430,534

Adjustments for Decrease (Increase) in Other Noncurrent Assets

pre_AdjustmentsForDecreaseIncreaseInOtherNoncurrentAssets

(499,966)

Adjustments for Decrease (Increase) in Other Noncurrent Assets

pre_AdjustmentsForDecreaseIncreaseInOtherNoncurrentAssets

(32,577)

Non Accrued Expenses and Other non Current Liabilities

pre_NonAccruedExpensesAndOtherNonCurrentLiabilities

16,561,122

Non Accrued Expenses and Other non Current Liabilities

pre_NonAccruedExpensesAndOtherNonCurrentLiabilities

36,280,298

Adjustments For Other Finance Costs

pre_AdjustmentsForOtherFinanceCosts

4,198,184

Adjustments For Other Finance Costs

pre_AdjustmentsForOtherFinanceCosts

5,238,030

Adjustments For Other Finance Costs

pre_AdjustmentsForOtherFinanceCosts

59,567

Amount Of Reclassification To Share Premium Due To Restructuring

pre_AmountOfReclassificationToSharePremiumDueToRestructuring

17,126,369

Reserves and Retained Earnings

pre_ReservesAndRetainedEarnings

237,050,429

Reserves and Retained Earnings

pre_ReservesAndRetainedEarnings

(400,811,431)

Adjustments For Increase (Decrease) In Receivables From Related Companies

pre_AdjustmentsForIncreaseDecreaseInReceivablesFromRelatedCompanies

9,060

Adjustments For Increase (Decrease) In Receivables From Related Companies

pre_AdjustmentsForIncreaseDecreaseInReceivablesFromRelatedCompanies

(9,060)

Adjustments For Fair Value Gain On Warrant Liabilities

pre_AdjustmentsForFairValueGainOnWarrantLiabilities

3,196,538

Expense Relating to Short-term Leases or Leases of Low-Value Assets for Which Recognition Exemption Has Been Used

pre_ExpenseRelatingToShortTermLeasesOrLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed

831,631

Expense Relating to Short-term Leases or Leases of Low-Value Assets for Which Recognition Exemption Has Been Used

pre_ExpenseRelatingToShortTermLeasesOrLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed

1,019,937

Expense Relating to Short-term Leases or Leases of Low-Value Assets for Which Recognition Exemption Has Been Used

pre_ExpenseRelatingToShortTermLeasesOrLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed

$ 429,691

Lease Term

pre_LeaseTerm

2 years

Lease Term

pre_LeaseTerm

10 years

Lease Term

pre_LeaseTerm

5 years

Number Of Shares Shares Not Issued Yet Due To Pending Statutory Procedures

pre_NumberOfSharesSharesNotIssuedYetDueToPendingStatutoryProcedures

1,543

Adjustments For Restructuring Costs In relation To Diagnostic Business

pre_AdjustmentsForRestructuringCostsInRelationToDiagnosticBusiness

$ 30,378,741

Adjustments for Decrease (Increase) in Due from Joint Venture

pre_AdjustmentsForDecreaseIncreaseInDueFromJointVenture

18,862

Deferred Tax Recognised Through Additions from Acquisition

pre_DeferredTaxRecognisedThroughAdditionsFromAcquisition

63,666

Deferred Tax Recognised Through Additions from Acquisition

pre_DeferredTaxRecognisedThroughAdditionsFromAcquisition

(235,879)

Deferred Tax Recognised Through Additions from Acquisition

pre_DeferredTaxRecognisedThroughAdditionsFromAcquisition

2,850,000

Deferred Tax Recognised Through Additions from Acquisition

pre_DeferredTaxRecognisedThroughAdditionsFromAcquisition

2,677,787

Adjustments For Share Based payment on listing

pre_AdjustmentsForShareBasedPaymentOnListing

89,546,601

Net Cash Outflow Arising Recognised As Of Acquisition Date

pre_NetCashOutflowArisingRecognisedAsOfAcquisitionDate

$ 3,418,715

Disclosure of Identifiable assets acquired and liabilities assumed [Table Text Block]

pre_DisclosureOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedTableTextBlock

The following table summarises the recognised amounts of assets acquired and liabilities assumed at the date of acquisition.


	$
Property, plant and equipment (note 11)		5,649,182
Intangible assets (note 12)		13,826,389
Interests in associates (note 14)		788,472
Deferred tax assets		235,879
Inventories		1,294,959
Trade receivables		2,594,976
Deposits, prepayments and other receivables		2,013,985
Cash and cash equivalents (note 33(A))		5,623,061
Trade payables		(857,537	)
Accrued expenses and other current liabilities		(2,763,480	)
Contract liabilities (note 21)		(416,307	)
Lease liabilities		(2,379,687	)
Tax liabilities		(5,713	)
Deferred tax liabilities		(2,913,666	)
Other non-current liabilities		(223,207	)

Total identifiable net assets acquired		22,467,306

Revenue from Funding Support of Employee Support Scheme

pre_RevenueFromFundingSupportOfEmployeeSupportScheme

$ 234,470

Revenue from Funding Support of Employee Support Scheme

pre_RevenueFromFundingSupportOfEmployeeSupportScheme

470,165

Accrued Expenses and Other Current Liabilities Recognised As of Acquisition Date

pre_AccruedExpensesAndOtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate

$ 2,763,480

Disclosure Of Changes In Goodwill Explanatory

pre_DisclosureOfChangesInGoodwillExplanatory

Goodwill arising from the acquisition has been recognized as follows.


	2022
	$
Consideration transferred (note 33(A))		49,783,820
Non-controlling interests, based on their proportionate interest in the recognized amounts of the assets and liabilities of ACT Genomics		6,483,762
Fair value of identifiable net assets (note 33(C))		(22,467,306	)

Goodwill (note 13)		33,800,276

Interests in Associates Recognised As of Acquisition Date

pre_InterestsInAssociatesRecognisedAsOfAcquisitionDate

$ 788,472

Share Price

pre_SharePrice

$ 2

Revenue from Funding Support of Jobs Support Scheme

pre_RevenueFromFundingSupportOfJobsSupportScheme

$ 7,932

Revenue from Funding Support of Jobs Support Scheme

pre_RevenueFromFundingSupportOfJobsSupportScheme

43,695

Revenue from Funding Support of Jobs Support Scheme

pre_RevenueFromFundingSupportOfJobsSupportScheme

300,208

Trade Receivables Recognised As of Acquisition Date

pre_TradeReceivablesRecognisedAsOfAcquisitionDate

2,594,976

Adjustments For Decrease Increase In Deferred Expenses

pre_AdjustmentsForDecreaseIncreaseInDeferredExpenses

(10,885,089)

Imputed Interest Expense on Deferred Consideration

pre_ImputedInterestExpenseOnDeferredConsideration

22,235

Imputed Interest Expense on Deferred Consideration

pre_ImputedInterestExpenseOnDeferredConsideration

9,513

Deposits Prepayments And Other Receivables Recognised As of Acquisition Date

pre_DepositsPrepaymentsAndOtherReceivablesRecognisedAsOfAcquisitionDate

2,013,985

Other Noncurrent Liabilities Recognised As Of Acquisition Date

pre_OtherNoncurrentLiabilitiesRecognisedAsOfAcquisitionDate

223,207

Lease Liabilities Recognised As of Acquisition Date

pre_LeaseLiabilitiesRecognisedAsOfAcquisitionDate

2,379,687

Adjustments for Increase (Decrease) in Deposits and Prepayments and Other Receivables

pre_AdjustmentsForIncreaseDecreaseInDepositsAndPrepaymentsAndOtherReceivables

1,213,944

Adjustments for Increase (Decrease) in Deposits and Prepayments and Other Receivables

pre_AdjustmentsForIncreaseDecreaseInDepositsAndPrepaymentsAndOtherReceivables

6,126,194

Adjustments for Increase (Decrease) in Deposits and Prepayments and Other Receivables

pre_AdjustmentsForIncreaseDecreaseInDepositsAndPrepaymentsAndOtherReceivables

1,093,451

Tax Liabilities Recognised As of Acquisition Date

pre_TaxLiabilitiesRecognisedAsOfAcquisitionDate

5,713

Increase Decrease Through Proceeds Interest Paid Liabilities Arising From Financing Activities

pre_IncreaseDecreaseThroughProceedsInterestPaidLiabilitiesArisingFromFinancingActivities

205,915

Increase Decrease Through Proceeds Interest Paid Liabilities Arising From Financing Activities

pre_IncreaseDecreaseThroughProceedsInterestPaidLiabilitiesArisingFromFinancingActivities

205,915

Increase Decrease Through Proceeds Interest Paid Liabilities Arising From Financing Activities

pre_IncreaseDecreaseThroughProceedsInterestPaidLiabilitiesArisingFromFinancingActivities

244,085

Increase Decrease Through Proceeds Interest Paid Liabilities Arising From Financing Activities

pre_IncreaseDecreaseThroughProceedsInterestPaidLiabilitiesArisingFromFinancingActivities

172,978

Increase Decrease Through Proceeds Interest Paid Liabilities Arising From Financing Activities

pre_IncreaseDecreaseThroughProceedsInterestPaidLiabilitiesArisingFromFinancingActivities

$ 417,063

Liabilities Incurred, First Portion

pre_LiabilitiesIncurredFirstPortion

$ 5,865,450

Liabilities Incurred, First Portion

pre_LiabilitiesIncurredFirstPortion

$ 7,549,258

Increase Through Acquisition Of Lease Liabilities

pre_IncreaseThroughAcquisitionOfLeaseLiabilities

2,379,687

Increase Through Acquisition Of Lease Liabilities

pre_IncreaseThroughAcquisitionOfLeaseLiabilities

2,379,687

Ifrs Convertible Notes Payable

pre_IfrsConvertibleNotesPayable

12,500,000

Ifrs Convertible Notes Payable

pre_IfrsConvertibleNotesPayable

$ 5,000,000

Ifrs Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms

pre_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms

4 years 8 months 12 days

Ifrs Stock Issued During Period, Shares, Conversion of Convertible Securities

pre_IfrsStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

2,729,893

Weighted Average Exercise Price Of Other Equity Instruments Cancelled In Share Based Payment Arrangement 2020

pre_WeightedAverageExercisePriceOfOtherEquityInstrumentsCancelledInShareBasedPaymentArrangement2020

$ 0.01

Schedule of Analysis of Expense Items in Relation to Leases [Table Text Block]

pre_ScheduleOfAnalysisOfExpenseItemsInRelationToLeasesTableTextBlock


	2022		2021		2020
	$		$		$
Depreciation charge of right-of-use assets by class of underlying asset:
- Properties leased for own use		2,039,815		1,535,333		575,787
- Office equipment		47,352		7,233		8,048

		2,087,167		1,542,566		583,835

Interest on lease liabilities (note 8(a))		244,085		205,915		49,400
Expense relating to short-term leases or leases of low-value assets		831,631		1,019,937		429,691

Convertible Non Redeemable Preference Share

pre_ConvertibleNonRedeemablePreferenceShare

$ 4.5789

Convertible Non Redeemable Preference Share

pre_ConvertibleNonRedeemablePreferenceShare

$ 6.6023

Borrowings, Fails to Repayment, Accrued Interest Rate

pre_BorrowingsFailsToRepaymentAccruedInterestRate

8.00%

Borrowings, Fails to Repayment, Accrued Interest Rate

pre_BorrowingsFailsToRepaymentAccruedInterestRate

8.00%

Selling and Distribution Expenses

pre_SellingAndDistributionExpenses

$ 13,301,436

Selling and Distribution Expenses

pre_SellingAndDistributionExpenses

21,932,322

Selling and Distribution Expenses

pre_SellingAndDistributionExpenses

$ 6,492,635

Borrowings, Redemption, Coupon Rate

pre_BorrowingsRedemptionCouponRate

2.00%

Borrowings, Redemption, Coupon Rate

pre_BorrowingsRedemptionCouponRate

2.00%

Disclosure of Detailed Information About Cash Flows for Leases Explantory

pre_DisclosureOfDetailedInformationAboutCashFlowsForLeasesExplantory


	2022			2021			2020
	$			$			$
Within operating cash flows		(831,631	)		(1,019,937	)		(429,691	)
Within financing cash flows		(2,121,981	)		(1,504,946	)		(660,326	)

		(2,953,612	)		(2,524,883	)		(1,090,017	)

Payment For Purchase Of Treasury Shares

pre_PaymentForPurchaseOfTreasuryShares

$ 661,519

Number Of Other Equity Instruments Cancelled In Share Based Payment Arrangement

pre_NumberOfOtherEquityInstrumentsCancelledInShareBasedPaymentArrangement

(75,031)

Number Of Other Equity Instruments Cancelled In Share Based Payment Arrangement

pre_NumberOfOtherEquityInstrumentsCancelledInShareBasedPaymentArrangement

(67,112)

Advances to Employees

pre_AdvancesToEmployees

$ 4,577,255

Advances to Employees

pre_AdvancesToEmployees

Payments Of Interest on Lease Liabilities Classified As Financing Activities

pre_PaymentsOfInterestOnLeaseLiabilitiesClassifiedAsFinancingActivities

244,085

Payments Of Interest on Lease Liabilities Classified As Financing Activities

pre_PaymentsOfInterestOnLeaseLiabilitiesClassifiedAsFinancingActivities

205,915

Payments Of Interest on Lease Liabilities Classified As Financing Activities

pre_PaymentsOfInterestOnLeaseLiabilitiesClassifiedAsFinancingActivities

49,400

Increase (Decrease) Through Changes In Carrying Value, Financial Liabilities

pre_IncreaseDecreaseThroughChangesInCarryingValueFinancialLiabilities

5,009,847

Increase (Decrease) Through Changes In Carrying Value, Financial Liabilities

pre_IncreaseDecreaseThroughChangesInCarryingValueFinancialLiabilities

Increase (Decrease) Through Changes In Carrying Value, Financial Liabilities

pre_IncreaseDecreaseThroughChangesInCarryingValueFinancialLiabilities

5,009,847

Increase (Decrease) Through Changes In Carrying Value, Financial Liabilities

pre_IncreaseDecreaseThroughChangesInCarryingValueFinancialLiabilities

3,752,758

Increase (Decrease) Through Changes In Carrying Value, Financial Liabilities

pre_IncreaseDecreaseThroughChangesInCarryingValueFinancialLiabilities

Increase (Decrease) Through Changes In Carrying Value, Financial Liabilities

pre_IncreaseDecreaseThroughChangesInCarryingValueFinancialLiabilities

$ 3,752,758

Disclosure Of Other Operating Income Expense [Table Text Block]

pre_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock


	2022			2021			2020
	$			$			$
Government subsidies (note)		534,678			7,932			513,860
Bank interest income		472,189			3,980			8,043
Dividend income		9,862			—			—
Net foreign exchange (losses)/gain s		(688,725	)		285,025			(280,360	)
Impairment loss on interest in a joint venture		—			—			(570,704	)
Impairment loss on amount due from a joint venture		—			(176,227	)		—
Sundry income		76,639			18,238			13,757

		404,643			138,948			(315,404	)

Payment for Acquire Financial Assets At Fair Value Through Profit Or Loss

pre_PaymentForAcquireFinancialAssetsAtFairValueThroughProfitOrLoss

$ 20,000,000

Payment for Acquire Financial Assets At Fair Value Through Profit Or Loss

pre_PaymentForAcquireFinancialAssetsAtFairValueThroughProfitOrLoss

10,000,000

Increase Through New Issues, Financial Liabilities

pre_IncreaseThroughNewIssuesFinancialLiabilities

18,954,939

Increase Through New Issues, Financial Liabilities

pre_IncreaseThroughNewIssuesFinancialLiabilities

7,015,061

Increase Through New Issues, Financial Liabilities

pre_IncreaseThroughNewIssuesFinancialLiabilities

25,970,000

Increase (Decrease) Through Changes In Fair Value, Financial Liabilities

pre_IncreaseDecreaseThroughChangesInFairValueFinancialLiabilities

Increase (Decrease) Through Changes In Fair Value, Financial Liabilities

pre_IncreaseDecreaseThroughChangesInFairValueFinancialLiabilities

125,398,798

Increase (Decrease) Through Changes In Fair Value, Financial Liabilities

pre_IncreaseDecreaseThroughChangesInFairValueFinancialLiabilities

125,398,798

Increase (Decrease) Through Changes In Fair Value, Financial Liabilities

pre_IncreaseDecreaseThroughChangesInFairValueFinancialLiabilities

Increase (Decrease) Through Changes In Fair Value, Financial Liabilities

pre_IncreaseDecreaseThroughChangesInFairValueFinancialLiabilities

60,091,353

Increase (Decrease) Through Changes In Fair Value, Financial Liabilities

pre_IncreaseDecreaseThroughChangesInFairValueFinancialLiabilities

60,091,353

Proceeds From Redemption Of Financial Assets At Fair Value through Profit Or Loss

pre_ProceedsFromRedemptionOfFinancialAssetsAtFairValueThroughProfitOrLoss

$ 3,004,897

Schedule of Results of Reportable Segments [Table Text Block]

pre_ScheduleOfResultsOfReportableSegmentsTableTextBlock


	Prevention		Diagnostics		Unallocated			Total
	$		$		$			$
2022
Revenue		15,774,457		259,986,841		—			275,761,298
Gross profit		6,538,453		127,180,380		(2,163,947	)		131,554,886
2021
Revenue		16,571,535		259,281,218		—			275,852,753
Gross profit		7,546,593		100,125,889		(1,541,271	)		106,131,211
2020
Revenue		14,264,972		50,914,543		—			65,179,515
Gross profit		6,332,833		20,983,200		(971,214	)		26,344,819

IFRS Number of Reportable Segments

pre_IfrsNumberOfReportableSegments

Schedule Of Details Of Other Equity Instruments Outstanding [Table Text Block]

pre_ScheduleOfDetailsOfOtherEquityInstrumentsOutstandingTableTextBlock

Details of the restricted share units outstanding as at December 31, 2022 and 2021 are as follows:


	Number of instruments
	2022		2021
Restricted share units granted to directors		1,636,011		11,900,009
Restricted share units granted to employees		43,045		2,033,151
Restricted share units granted to third parties		11,710		815,057

		1,690,766		14,748,217

IFRS Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

pre_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock


	2022			2021			2020
	$			$			$
Loss before taxation		(183,306,283	)		(170,284,098	)		(3,901,443	)

Notional tax on loss before taxation, calculated at the applicable rate		(18,117,948	)		(6,622,976	)		(697,772	)
Tax effect of non-deductible expenses		25,595,035			11,587,117			1,111,877
Tax effect of non-taxable income		(168,565	)		(1,008,915	)		(76,874	)
Tax effect of temporary difference not recognized		—			—			73,833
Tax effect on utilization of previously unrecognized tax losses		—			(579,657	)		(692,350	)
Tax effect of tax losses not recognized		101,854			—			298,651
Tax effect of previously unrecognized temporary differences recognized in current year		(263,272	)		360,922			(1,957,229	)
Others		—			(3,747	)		2,306

		7,147,104			3,732,744			(1,937,558	)

Decrease Through Reclassification To Preference Shares Liabilities, Equity

pre_DecreaseThroughReclassificationToPreferenceSharesLiabilitiesEquity

$ (37,890,771)

Decrease Through Reclassification To Preference Shares Liabilities, Equity

pre_DecreaseThroughReclassificationToPreferenceSharesLiabilitiesEquity

(241,942,035)

Decrease Through Reclassification To Preference Shares Liabilities, Equity

pre_DecreaseThroughReclassificationToPreferenceSharesLiabilitiesEquity

(279,832,806)

Decrease Through Reclassification To Preference Shares Liabilities, Equity

pre_DecreaseThroughReclassificationToPreferenceSharesLiabilitiesEquity

(279,832,806)

Decrease Through Reclassification To Preference Shares Liabilities, Equity

pre_DecreaseThroughReclassificationToPreferenceSharesLiabilitiesEquity

5,116

Decrease Through Reclassification To Preference Shares Liabilities, Equity

pre_DecreaseThroughReclassificationToPreferenceSharesLiabilitiesEquity

550,243,765

Decrease Through Reclassification To Preference Shares Liabilities, Equity

pre_DecreaseThroughReclassificationToPreferenceSharesLiabilitiesEquity

550,248,881

Decrease Through Reclassification To Preference Shares Liabilities, Equity

pre_DecreaseThroughReclassificationToPreferenceSharesLiabilitiesEquity

$ 550,248,881

Weighted Average Fair Value of Other Equity Instruments Granted in Sharebased Payment Arrangement

pre_WeightedAverageFairValueOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement

$ 1.091

Trade Receivables Period

pre_TradeReceivablesPeriod

30 days

Trade Receivables Period

pre_TradeReceivablesPeriod

60 days

Increase (Decrease) Through Change In Fair Value Of Convertible Securities, Equity

pre_IncreaseDecreaseThroughChangeInFairValueOfConvertibleSecuritiesEquity

$ (811,819)

Increase (Decrease) Through Change In Fair Value Of Convertible Securities, Equity

pre_IncreaseDecreaseThroughChangeInFairValueOfConvertibleSecuritiesEquity

(811,819)

Increase (Decrease) Through Change In Fair Value Of Convertible Securities, Equity

pre_IncreaseDecreaseThroughChangeInFairValueOfConvertibleSecuritiesEquity

(811,819)

IFRS Profit (loss)

pre_IfrsProfitLoss

190,453,387

IFRS Profit (loss)

pre_IfrsProfitLoss

174,016,842

IFRS Profit (loss)

pre_IfrsProfitLoss

1,963,885

Ifrs Payment for Contingent Consideration Liability, Financing Activities

pre_IfrsPaymentForContingentConsiderationLiabilityFinancingActivities

$ 1,326,823

Schedule Of Financial Assets At Fair Value Through Profit Or Loss [Table Text Block]

pre_ScheduleOfFinancialAssetsAtFairValueThroughProfitOrLossTableTextBlock


	2022 $		2021 $
Financial assets measured at fair value through profit or loss (“FVPL”)
- Unlisted securities		17,537,608		9,906,000

Common Stock, Number of Votes

pre_CommonStockNumberOfVotes

Fair Value At Measurement Date, Share Price, Other Equity Instruments Granted

pre_FairValueAtMeasurementDateSharePriceOtherEquityInstrumentsGranted

$ 13.89

Fair Value At Measurement Date, Share Price, Other Equity Instruments Granted

pre_FairValueAtMeasurementDateSharePriceOtherEquityInstrumentsGranted

18.91

Weighted Average Share Price, Other Equity Instruments Granted

pre_WeightedAverageSharePriceOtherEquityInstrumentsGranted

13.89

Weighted Average Share Price, Other Equity Instruments Granted

pre_WeightedAverageSharePriceOtherEquityInstrumentsGranted

$ 18.91

Impairment Loss on Interest in Joint Venture

pre_ImpairmentLossOnInterestInJointVenture

$ 570,704

Exercise Price, Other Equity Instruments Granted

pre_ExercisePriceOtherEquityInstrumentsGranted

$ 0.01

Expected Volatility, Other Equity Instruments Granted

pre_ExpectedVolatilityOtherEquityInstrumentsGranted

41.03%

Expected Volatility, Other Equity Instruments Granted

pre_ExpectedVolatilityOtherEquityInstrumentsGranted

44.26%

Expected Option Life, Other Equity Instruments Granted

pre_ExpectedOptionLifeOtherEquityInstrumentsGranted

1 year

Schedule Of Changes In Financial Assets At Fair Value Through Profit Or Loss [Table Text Block]

pre_ScheduleOfChangesInFinancialAssetsAtFairValueThroughProfitOrLossTableTextBlock

Movement of the balance during the year ended December 31, 2022 and 2021 is as follow:


	2022 $			2021 $
At January 1		9,906,000			—
Additions		20,000,000			10,000,000
Redemption		(3,004,897	)		—
Changes in fair value recognized in profit or loss		(9,363,495	)		(94,000	)

At December 31		17,537,608			9,906,000

Risk Free Interest Rate, Other Equity Instruments Granted

pre_RiskFreeInterestRateOtherEquityInstrumentsGranted

1.00%

Risk Free Interest Rate, Other Equity Instruments Granted

pre_RiskFreeInterestRateOtherEquityInstrumentsGranted

1.13%

Expected Dividend As Percentage, Other Equity Instruments Granted

pre_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted

0.00%

Reclassification Of Preference Share Liabilities To Share Capital And Share Premium Upon Listing

pre_ReclassificationOfPreferenceShareLiabilitiesToShareCapitalAndSharePremiumUponListing

$ (65,125,911)

Reclassification Of Preference Share Liabilities To Share Capital And Share Premium Upon Listing

pre_ReclassificationOfPreferenceShareLiabilitiesToShareCapitalAndSharePremiumUponListing

(485,122,970)

Reclassification Of Preference Share Liabilities To Share Capital And Share Premium Upon Listing

pre_ReclassificationOfPreferenceShareLiabilitiesToShareCapitalAndSharePremiumUponListing

(550,248,881)

Increase Decrease Through Reverse Recapitalization Equity

pre_IncreaseDecreaseThroughReverseRecapitalizationEquity

1,452

Increase Decrease Through Reverse Recapitalization Equity

pre_IncreaseDecreaseThroughReverseRecapitalizationEquity

113,144,754

Increase Decrease Through Reverse Recapitalization Equity

pre_IncreaseDecreaseThroughReverseRecapitalizationEquity

113,146,206

Increase Decrease Through Reverse Recapitalization Equity

pre_IncreaseDecreaseThroughReverseRecapitalizationEquity

113,146,206

Non-current assets Excluding Interest in Joint Venture and Deferred Tax Assets